Alcoholic liver disease medical therapy

Jump to navigation Jump to search

Alcoholic liver disease Microchapters


Patient Information


Historical Perspective




Differentiating Alcoholic liver disease from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alcoholic liver disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Alcoholic liver disease medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alcoholic liver disease medical therapy

CDC on Alcoholic liver disease medical therapy

Alcoholic liver disease medical therapy in the news

Blogs on Alcoholic liver disease medical therapy

Directions to Hospitals Treating Alcoholic liver disease

Risk calculators and risk factors for Alcoholic liver disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2] Aditya Govindavarjhulla, M.B.B.S. [3]


The most important part of treatment is to stop using alcohol completely. If liver cirrhosis has not yet occurred, the liver can heal if you stop drinking alcohol. An alcohol rehabilitation program or counseling may be necessary to break the alcohol addiction. Vitamins, especially B-complex and folic acid, can help reverse malnutrition. If cirrhosis develops, there is a need to manage the complications of cirrhosis. It may need a liver transplant.

Medical therapy[edit]

General Therapy[edit]

General therapy for alcoholic liver disease includes:<ref name="pmid19745759">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid19788058">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid19489992">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid8925349">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid15200577">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid10208148">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid19630744">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid18068515">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid7672043">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid1476147">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid8985274">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid15349806">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid16099027">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid9820369">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>


Alcoholic hepatitis[edit]

  • Glucocorticoids<ref name="pmid19389182">{{#invoke:Citation/CS1|citation

|CitationClass=journal }}</ref><ref name="pmid11943428">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid1531090">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid2648927">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid352788">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid18363896">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid16503078">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="urlLilleModel">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

|CitationClass=journal }}</ref><ref name="pmid19575503">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid11113085">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid18164508">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid19340904">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid19821406">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

  • Other less commonly used drugs<ref name="pmid14745316">{{#invoke:Citation/CS1|citation

|CitationClass=journal }}</ref><ref name="pmid15240996">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid12163148">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid2671116">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name="pmid9566830">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

==2010 AASLD/ACG Alcoholic Liver Disease Guidelines (DO NOT EDIT)<ref name="">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>== ===Abstinence (DO NOT EDIT)<ref name="">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>===

Class I
1. " In patients with evidence of alcohol-induced liver disease, strict abstinence must be recommended, because continued alcohol use is associated with disease progression.(Level of evidence: B) "
2. " Naltrexone or acamprosate may be considered in combination with counseling to decrease the likelihood of relapse in patients with alcohol abuse/dependence in those who achieve abstinence. (Level of evidence: A) "

===Treatment of Alcohol Hepatitis (DO NOT EDIT)<ref name="">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>===

Class I
1. " All patients with alcoholic hepatitis should be counseled to completely abstain from alcohol. (Level of evidence: B) "
2." All patients with alcoholic hepatitis or advanced ALD should be assessed for nutritional deficiencies (protein-calorie malnutrition), as well as vitamin and mineral deficiencies. Those with severe disease should be treated aggressively with enteral nutritional therapy.(Level of evidence: B)"
3." Patients with severe disease (MDF score of >32, with or without hepatic encephalopathy) and lacking contraindications to steroid use should be considered for a four week course of prednisolone (40 mg/day for 28 days, typically followed by discontinuation or a 2-week taper).(Level of evidence: A)"
4." Patients with severe disease (i.e., a MDF >32) could be considered for pentoxifylline therapy (400 mg orally 3 times daily for 4 weeks), especially if there are contraindications to steroid therapy.(Level of evidence: B)"
Class III (No Benefit)
1. " Patients with mild-moderate alcoholic hepatitis—defined as a Maddrey score of <32, without hepatic encephalopathy, and with improvement in serum bilirubin or decline in the MDF during the first week of hospitalization—should be monitored closely, but will likely not require nor benefit from specific medical interventions other than nutritional support and abstinence.(Level of evidence: A)"

===Long-term Management (DO NOT EDIT)<ref name="">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>===

Class I
1." Patients with alcoholic cirrhosis should receive frequent interval feedings, emphasizing a night time snack and morning feeding, to improve nitrogen balance. (Level of evidence: B) "
Class III (No Benefit)
1. "Propylthiouracil (PTU) and colchicine should not be used in the treatment of patients with ALD; S-adenosyl L-methionine (SAMe) should be used only in clinical trials.(Level of evidence: A)"
2. "The use of complementary or alternative medicines in the treatment of either acute or chronic alcohol-related liver disease has shown no convincing benefit and should not be used out of the context of clinical trial.(Level of evidence: A)"


<references group="" responsive="0"></references>

{{#invoke:Check for unknown parameters|check|unknown=|preview=Page using Template:Reflist with unknown parameter "_VALUE_"|ignoreblank=y| 1 | colwidth | group | liststyle | refs }}

Template:WS Template:WH